Market news

Earning a spot on the IBD Leaderboard and IBD 50, Guardant Health stress tests a breakout.

Guardant Health (NasdaqGS:GH) received FDA approval for its Guardant360 CDx liquid biopsy as a companion diagnostic in advanced HR-positive, HER2-negative breast cancer. The decision makes Guardant360 CDx the first FDA approved liquid biopsy companion diagnostic for longitudinal ctDNA testing in breast cancer care. The approval is supported by clinical trial data where early detection of ESR1 mutations using Guardant360 CDx informed treatment changes for patients. The Guardant360 CDx breast...

The Dow Jones index sold off more than 600 points Wednesday after the Fed's rate hike and Fed Chair Kevin Warsh's hawkish comments.

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Guardant Health (NASDAQ:GH) and its peers.

Guardant Health provides services across the cancer continuum as its stock nears a buy point of 176.58 after a breakout.

PALO ALTO, Calif., September 14, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer screening (CRC) will be covered in EviCore by Evernorth clinical guidelines effective January 1, 2027, per ACS guidelines. EviCore is a Cigna-owned company and the second largest specialty benefits manager in the country spanning more than 23 states.

Guardant Health (GH) has an average rating of buy and mean price target of $198.38, according to ana

Artisan Partners, an investment management company, released its second-quarter 2026 investor letter for the “Artisan Mid Cap Fund”. The letter can be downloaded here. Global equities rebounded sharply in Q2 2026, recovering from March lows as resilient economic data, strong corporate earnings, and continued AI investment improved investor sentiment despite inflation concerns, delayed rate cuts, and […]

PALO ALTO, Calif., September 08, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it has been named to Business Insider’s America's Most Innovative Businesses 2027 list, earning the highest rating available with a five-star recognition awarded to only other 12 biotechnology research companies in the category.

Guardant Health, Inc. (NASDAQ:GH) faces a costly legal setback after a US court ordered the cancer-testing company to pay more than $245.2 million in a DNA-sequencing patent dispute. The final judgment upheld a 2023 jury verdict finding that Guardant willfully infringed two DNA-sequencing patents asserted by TwinStrand Biosciences and the University of Washington. The financial […]

PALO ALTO, Calif., September 04, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic (CDx) to identify patients with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer harboring tumors with ESR1 mutations before radiographic progression who may benefit from treatment with ETCAMAH™ (camizestrant), AstraZeneca’s next-ge

Guardant Health stock has delivered very strong gains over the past three years, yet its valuation signals are split, with the intrinsic value estimate pointing to upside while broader checks suggest the shares are not a clear bargain. After a recent legal setback and a sharp multi year rise, investors are weighing how much of Guardant Health’s growth potential is already reflected in the current price. Guardant Health has returned about 327.6% over the past three years, which puts more...

In August 2026, a U.S. district court entered final judgment that Guardant Health infringed TwinStrand Biosciences and University of Washington DNA sequencing patents, ordering more than US$245.2 million in damages, accrued royalties and interest plus ongoing royalties on 11 products through March 2033. Guardant has said it will appeal and highlighted that updated versions of key tests, including Guardant Reveal and Shield, are excluded from the royalty order, while it continues to challenge...

Guardant Health (GH) is back in focus after a U.S. district court ordered the company to pay more than US$245.2 million in a patent dispute with TwinStrand Biosciences and the University of Washington. Guardant Health shares have been volatile around the legal headlines. The stock still has a 30 day share price return of 17.5% and a year to date share price return of 68.0%, while the 1 year total shareholder return of 169.17% and 3 year total shareholder return of more than 3x suggest...

A U.S. court ruled Guardant willfully infringed two core patents for DNA sequencing methods in a case brought by TwinStrand Biosciences and the University of Washington.

Guardant plans to appeal the ruling, taking particular issue with a 6% ongoing royalties stipulate outlined in the court’s motion.

PALO ALTO, Calif., August 24, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will appeal the final judgment from the U.S. District Court for the District of Delaware related to intellectual property claims brought against Guardant by TwinStrand Biosciences, Inc. and University of Washington, with execution of the final judgment and collection of potential royalties stayed pending appeal.

Guardant Health stock tumbled Monday after losing a patent battle against privately held TwinStrand Biosciences.

SEATTLE, August 24, 2026--TwinStrand Biosciences (TwinStrand), the pioneer in Duplex Sequencing® technology, today announced that the U.S. District Court for the District of Delaware entered final judgment on Aug. 21, 2026, in favor of TwinStrand and the University of Washington (UW) in their patent infringement suit against Guardant Health, Inc. (Nasdaq: GH). The final judgment preserves a November 2023 jury verdict finding that Guardant Health willfully infringed two core patents underlying Tw

Guardant Health (GH) said Monday it will appeal the final judgment of a Delaware district court rela

Aristotle Capital Management, LLC, an investment management company, released its “Core Equity Fund” Q2 2026 investor letter. A copy of the letter can be downloaded here. The fund returned 14.69% in the second quarter of 2026, slightly trailing the 15.20% gain of the S&P 500 Index as market performance remained highly concentrated in artificial intelligence (AI)-related […]

Terilyn J. Monroe, Chief People Officer, on August 12, 2026, sold 46,300 shares in Guardant Health (

Guardant Health (GH) just reported its second quarter 2026 results, with sales of US$334.98 million and a net loss of US$120.14 million, and simultaneously raised its full year 2026 revenue guidance. See our latest analysis for Guardant Health. Guardant Health’s latest earnings release, stronger revenue guidance for 2026 and the recent shelf registration filing come after a powerful run in the stock, with a 90 day share price return of 67.66% and a 1 year total shareholder return of 199.62%...

Guardant Health, Inc. is rated a Buy and is experiencing robust growth, driven by its MRD and screening businesses. Read more on GH stock here.

PALO ALTO, Calif., August 10, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on July 21, 2026, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units ("RSUs") representing 46,044 shares of its common stock to 149 new non-executive employees with a grant date of August 3, 2026, under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the "Inducement Plan"). The RSUs w

Detailed price information for Unitedhealth Group (UNH-N) from The Globe and Mail including charting and trades.

Shield screening volumes more than doubled, with UnitedHealth coverage now active.

Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]

Diagnostics company Guardant Health (NASDAQ:GH) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 44.3% year on year to $335 million. The company’s full-year revenue guidance of $1.35 billion at the midpoint came in 2.7% above analysts’ estimates. Its non-GAAP loss of $0.42 per share was 7.8% below analysts’ consensus estimates.